Papers in EJC Paediatric Oncology
Page 5 · newest first
- Coping strategies in families who lost a child to cancer: A scoping reviewEJC Paediatric Oncology · 2023
- A decade of FDA approvals for pediatric cancer indications: What have we learned?EJC Paediatric Oncology · 2023
- Outcome of children with relapsed acute myeloid leukemia improved over time in the Netherlands between 1998 and 2018EJC Paediatric Oncology · 2023
- Imaging recommendations for the management of pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Consensus statement of the International Soft Tissue Sarcoma Consortium (INSTRuCT)EJC Paediatric Oncology · 2023
- Refractory and relapsed paediatric ACC in the MET studies – A challenging situation necessitating novel diagnostic and therapeutic conceptsEJC Paediatric Oncology · 2023
- Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastomaEJC Paediatric Oncology · 2023
- Adolescents and young adults with cancer: Surfing the web to know and manage their diseaseEJC Paediatric Oncology · 2023
- A meta-analysis on the diagnostic performance of whole-body MRI for the initial staging of Hodgkin lymphoma in children and adults using FDG-PET/CT as a reference standardEJC Paediatric Oncology · 2023
- Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to ageEJC Paediatric Oncology · 2023
- Hearing loss after exposure to vincristine and platinum-based chemotherapy among childhood cancer survivorsEJC Paediatric Oncology · 2023
- The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemiaEJC Paediatric Oncology · 2023
- Recommending exercise and sports for children and adolescents with a solitary kidney after a renal tumor: A view on current evidence-based risks and decisionsEJC Paediatric Oncology · 2023
- Time to broaden the eligibility criteria in paediatric oncology trials? An analysis of patients with rhabdomyosarcoma non-eligible to the EpSSG RMS2005 trialEJC Paediatric Oncology · 2023
- Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergyEJC Paediatric Oncology · 2022